Kodak’s Continenza Cagey About Pharma Future
Company Says It Is Cooperating With Insider Trading Investigations
Kodak CEO Jim Continenza is revealing nothing about ongoing investigations, which leave Kodak’s plans to venture into pharmaceuticals – along with a $765m federal loan – uncertain.
You may also be interested in...
Kelix bio has announced two deals to expand its presence in Africa. The company is set to acquire 14 oncology injectable products from Germany-based Vitane. Furthermore, Kelix has acquired Pharmaceutical Institute, a pharmaceutical company established in Rabat, to enter Morocco. The pan-African company has also invested in Malta.
Cipla has partnered with mAbxience to supply oncology and respiratory-related biosimilars on the WHO model list of essential medicines to South Africa.
British Columbia has added three new biosimilar versions of the anti-clotting drug enoxaparin to PharmaCare, including Redesca, Noromby and Inclunox. The move comes after the Canadian province recently included additional biosimilars in its switching program.